secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0001104659-24-026336
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise posts Q4 net loss $0.47/sh; pro-forma cash >$550M; multiple trial readouts in 2024
--------------------------------------------------------------------------------

- Net loss for Q4 2023 was $30.1M ($0.47 per share), up from $25.7M ($0.41) in Q3 2023.
- Cash, equivalents and marketable securities $318.4M at Dec 31, 2023; pro-forma >$550M after $231.8M net Jan 2024 offering.
- R&D expenses $27.7M (+$3.9M QoQ); G&A $6.2M (+$0.5M QoQ) as clinical programs advanced.
- Expect CANYON (Becker) data Q4 2024; ARCH 24-month, DUNE, and LYNX dose data in Q2 2024.
- EDG-7500 Phase 1 data and Phase 2 obstructive HCM data expected Q3 2024; FOX trial dosing starts early 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000110465924026336/0001104659-24-026336-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000110465924026336/tm246960d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-026336

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer